OBIO CAAP Company CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial

CellAegis Devices announced enrollment of the first patients in a U.S. clinical trial of its autoRIC® device. The autoRIC® device automatically delivers remote ischemic conditioning to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures. 

Click here to read the full release